Free Trial
NASDAQ:NXTC

NextCure Q1 2024 Earnings Report

NextCure logo
$0.47 -0.03 (-5.64%)
As of 04:00 PM Eastern

NextCure EPS Results

Actual EPS
-$0.61
Consensus EPS
-$0.45
Beat/Miss
Missed by -$0.16
One Year Ago EPS
N/A

NextCure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NextCure Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 2, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

NextCure's Q1 2025 earnings is scheduled for Thursday, May 1, 2025

NextCure Earnings Headlines

"I'm risking my reputation on this"
I've discovered something so significant about the 2025 crypto market that I had to put everything else aside and write a book about it. This isn't just another Bitcoin prediction – it's a complete roadmap for what I believe will be the biggest wealth-building opportunity of this decade. The evidence is so compelling, I'm doing something that probably seems insane: I'm giving away my entire book for free.
Piper Sandler Sticks to Its Buy Rating for NextCure (NXTC)
See More NextCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NextCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NextCure and other key companies, straight to your email.

About NextCure

NextCure (NASDAQ:NXTC), a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

View NextCure Profile

More Earnings Resources from MarketBeat